Lenzumestrocel

BIOLOGICAL2 trials

Sponsors

Corestemchemon, Inc.

Conditions

Amyotrophic Lateral Sclerosis

Phase 1

Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS

CompletedNCT06676423

Corestemchemon, Inc.Amyotrophic Lateral Sclerosis

Start: 2022-11-09End: 2023-11-27Updated: 2024-11-06

Phase 3

Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS

CompletedNCT04745299

Corestemchemon, Inc.Amyotrophic Lateral Sclerosis

Start: 2021-02-24End: 2024-11-13Updated: 2026-04-30

Related Papers

Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial

Trials2022-05-1815 citations